Brand Spotlight: Novo Nordisk’s Semaglutide
In Vivo’s ‘Brand Spotlight’ provides an in-depth look at individual brands with unique or exemplary product journeys – from novel development programs to formidable commercial strategies.
Novo Nordisk’s semaglutide, a GLP-1 agonist marketed in an injected formulation as Ozempic, and an oral tablet form as Rybelsus, is a success story with the potential for an epic third act. First approved as a treatment for type 2 diabetes, semaglutide is under FDA review as a treatment for obesity, with additional clinical programs in NASH and Alzheimer’s disease.
You may also be interested in...
BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies.
Novo Nordisk was not the first biopharmaceutical company to launch a GLP-1 therapy into the market for type 2 diabetes. In fact, Amylin Pharmaceutials’ and Eli Lilly’s Byetta (exenatide) beat Novo’s Victoza (liraglutide) to market by a full five years.
Keeping Track: Zegalogue Joins Hypoglycemia Space; Keytruda Earns First-Line Esophageal Cancer Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker